Parents heading into the 2026–2027 respiratory season face more options for protecting infants from RSV than at any point in the last decade. This week’s independent evidence review and new modeling analyses sharpen the picture of what works, while early case signals and a second long-acting antibody option keep the practical questions open.
Background
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants. Virtually all children are infected by age two. For most older children it is a cold; for infants under six months, especially those born preterm or with lung or heart conditions, it can cause bronchiolitis and pneumonia severe enough to require oxygen or intensive care. Before 2023 the only passive option for high-risk infants was monthly palivizumab. That changed with the approval of nirsevimab (Beyfortus), a long-acting monoclonal antibody given as a single dose for the first season, and the maternal RSV vaccine (Abrysvo) given in late pregnancy so antibodies transfer to the baby. In 2025 Merck’s clesrovimab (Enflonsia) received U.S. approval as another fixed-dose, non-weight-based long-acting antibody for the first season.
What changed this week
An independent evidence review coordinated by the Vaccine Integrity Project and the American Medical Association reaffirmed that influenza, RSV, and COVID-19 immunizations continue to protect infants and children against severe outcomes, with no new pediatric safety signals. For RSV specifically, maternal vaccination reduced infant hospitalization risk by roughly 51–70 percent, while nirsevimab reduced first-season RSV hospitalization risk by 64–93 percent across studies. A separate U.S. modeling analysis published this week concluded that nirsevimab would avert the largest absolute number of RSV lower-respiratory events and hospitalizations compared with clesrovimab or maternal vaccination alone, and would be the most cost-effective of the three strategies at current prices. Infants born outside the classic October–March window still account for a substantial share of hospitalizations, reinforcing the case for year-round eligibility windows in many regions.
Separately, the FDA accepted Merck’s application to expand Enflonsia to high-risk children under age two entering a second RSV season, with a decision expected in March 2027. European regulators have already approved the product for first-season use without weight-based dosing.
Early surveillance notes from some U.S. health systems describe an earlier-than-typical rise in RSV detections as flu season also begins.
Competing viewpoints
Pediatric infectious-disease groups and the AAP continue to recommend that every infant under eight months entering the first RSV season receive either maternal vaccination (if given at least 14 days before delivery) or a long-acting antibody. They emphasize that the two approaches are generally not stacked for the same baby unless timing or risk factors require it.
Some cost-effectiveness modelers argue that, at current acquisition prices, nirsevimab delivers the greatest population-level impact. Others note that real-world uptake, supply constraints, and the fact that many births occur outside the peak season can change the ranking. A minority of voices, largely outside mainstream pediatrics, continue to question the absolute benefit size or raise theoretical concerns about antibody interference; the independent review found no supporting safety signals in the pediatric data examined.
What to watch next
- Whether the early RSV signal this fall materializes into a true earlier peak, and how clinics manage antibody supply if it does.
- FDA’s March 2027 decision on second-season Enflonsia for high-risk children, and any parallel AAP or CDC guidance updates.
- Real-world effectiveness and equity data on which infants actually receive protection before discharge or at the first well-baby visit.
- Any updates to the maternal vaccine window or recommendations for spring and summer births.
For tonight: if your baby is under eight months and has not yet received RSV protection, ask the pediatric office or birth hospital this week whether a dose is planned. The evidence review and modeling both point to the same practical conclusion—getting one of the approved tools in place before the season peaks remains the highest-leverage step available to most families.
Sources: Contemporary Pediatrics summaries of the Vaccine Integrity Project/AMA review and the nirsevimab modeling analysis (15–16 October 2026); Merck and FDA announcements on the Enflonsia second-season filing; CDC and pediatric society guidance on 2026–2027 RSV immunization.
Comments (0)
No comments yet.
Sign in to comment.